John G Ullman & Associates Inc. Has $3.65 Million Stock Holdings in Pfizer Inc. $PFE

John G Ullman & Associates Inc. lessened its holdings in shares of Pfizer Inc. (NYSE:PFE) by 42.3% in the 2nd quarter, according to its most recent filing with the SEC. The fund owned 150,703 shares of the biopharmaceutical company’s stock after selling 110,464 shares during the period. John G Ullman & Associates Inc.’s holdings in Pfizer were worth $3,653,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in PFE. Pacer Advisors Inc. lifted its position in shares of Pfizer by 856.8% during the 1st quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company’s stock worth $508,164,000 after purchasing an additional 17,957,928 shares during the last quarter. Amundi raised its holdings in Pfizer by 43.4% in the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock valued at $1,265,277,000 after acquiring an additional 15,758,846 shares in the last quarter. Nuveen LLC acquired a new position in Pfizer in the 1st quarter valued at approximately $389,861,000. Goldman Sachs Group Inc. raised its holdings in Pfizer by 51.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company’s stock valued at $670,407,000 after acquiring an additional 9,041,990 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in Pfizer by 0.9% in the 1st quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company’s stock valued at $13,257,004,000 after acquiring an additional 4,629,976 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Wall Street Zen cut Pfizer from a “buy” rating to a “hold” rating in a report on Sunday, September 28th. Morgan Stanley cut their price target on Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a report on Friday, October 10th. Bank of America upped their price target on Pfizer from $28.00 to $30.00 and gave the company a “neutral” rating in a report on Friday, October 3rd. Finally, UBS Group reaffirmed a “neutral” rating and issued a $28.00 price target on shares of Pfizer in a report on Wednesday, October 1st. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $28.13.

Pfizer Trading Up 1.2%

PFE stock opened at $24.52 on Friday. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $29.36. The firm has a market cap of $139.38 billion, a P/E ratio of 13.04, a P/E/G ratio of 0.81 and a beta of 0.55. The business’s 50 day moving average is $24.89 and its 200-day moving average is $24.11. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same period in the prior year, the company posted $0.60 EPS. The company’s revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a yield of 7.0%. Pfizer’s dividend payout ratio is 91.49%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.